ArticlePediatric nephrology (Berlin, Germany)2017
Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Article in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Guideline
- Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial.Pediatric nephrology (Berlin, Germany) · 2020Trial
- Trial
- Subcutaneous ofatumumab for remission maintenance in pediatric idiopathic nephrotic syndrome: a case series.Clinical kidney journal · 2026Article
- Severe anaphylactic shock reaction upon rituximab rechallenge in membranous nephropathy: a case report and literature review.Frontiers in pharmacology · 2026Article
- Obinutuzumab in kidney transplantation: Past, present, and future.World journal of transplantation · 2025Review
- Successful Switch to Obinutuzumab in a Rituximab-Intolerant Child with Difficult-to-Treat Idiopathic Nephrotic Syndrome.Journal of clinical medicine · 2025Article
- B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease.Current neurology and neuroscience reports · 2024Review
- Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment.Frontiers in immunology · 2023Review
- An updated view of the pathogenesis of steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2022Review
- Update on the treatment of steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2022Review
- New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?Frontiers in immunology · 2022Review
- UK experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant.Pediatric nephrology (Berlin, Germany) · 2022Article
- Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives.Frontiers in immunology · 2022Review
- Current understandings in treating children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021Review
- Ofatumumab treatment for nephrotic syndrome recurrence after pediatric renal transplantation.Pediatric nephrology (Berlin, Germany) · 2020Article
- Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome.CEN case reports · 2020Article
- Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness.BMJ case reports · 2020Article
- Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.Pediatric nephrology (Berlin, Germany) · 2018Review
- Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ.Pediatric rheumatology online journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment in steroid-dependent nephrotic syndrome (SDNS). However, some patients develop adverse reactions. CASE-DIAGNOSIS/TREATMENT: Patient 1, a 14-year-old boy with SDNS since the age of 2, was treated with oral prednisone, cyclosporine A (CsA) and mycophenolate mofetil. A first infusion of rituximab at age 12 years was well tolerated, but this was followed by a prolonged relapse unresponsive to oral prednisone, mycophenolate mofetil and CsA. A second rituximab infusion was attempted, but treatment was interrupted due to severe dyspnea. Treatment with a humanized anti-CD20 monoclonal antibody, ofatumumab, was then attempted. The patient experienced a mild allergic reaction and maintained remission despite interruption of all treatment at >12 months of follow-up. Patient 2, a 3-year-old boy who presented at 18 months with nephrotic syndrome initially resistant to treatment with oral prednisone, was given with three intravenous boluses of methylprednisolone followed by CsA and achieved remission. Upon steroid discontinuation, the NS relapsed. Prednisone was restarted and treatment with a single dose of rituximab was never completed due to a severe allergic reaction. Ofatumumab infusion was uneventful, and he maintained remission during the follow-up period (>12 months) despite interruption of prednisone therapy. B cells reappeared at 7 months in both patients.
conclusionsOfatumumab may be a therapeutic option in severe forms of NS with allergy to rituximab.
Indexed as
Identifiers
27687621What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.